# Phase I - Serological Assays for the detection and characterization of influenza viruses

Canonical: https://abierto.us/opportunities/75d30125r73211phasei

- Solicitation number: 75D30125R73211_Phase_I
- Notice type: Solicitation
- Status: Closed. Deadline was November 21, 2024 at 2:00 PM EST
- Department: Department of Health and Human Services
- Agency: Centers for Disease Control and Prevention
- Contracting office: CDC Office of Acquisition Services (75D301)
- NAICS: 325413 In-Vitro Diagnostic Substance Manufacturing
- Product or service code: Q301 Reference Laboratory Testing
- Set-aside: Total small business set-aside
- Place of performance: Atlanta, Georgia
- City: Atlanta. https://abierto.us/cities/atlanta-ga-1304000
- First posted: November 14, 2024
- Last posted: November 14, 2024
- SAM.gov: https://sam.gov/workspace/contract/opp/9b7ce42c9dbe49d7b0d808b6f8712ffd/view

## Description

The objective of this contract is to support the Influenza Division through the testing of human sera via hemagglutination inhibition assay as well as develop a new serology platform that is comparable to hemagglutination inhibition assay.

## Publications

- November 14, 2024: Solicitation, due November 21, 2024 at 2:00 PM EST. Notice 9b7ce42c9dbe49d7b0d808b6f8712ffd. https://sam.gov/workspace/contract/opp/9b7ce42c9dbe49d7b0d808b6f8712ffd/view

## Points of contact

- Jennifer Gartzke, jgartzke@cdc.gov, 4044980020

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/75d30125r73211phasei.